Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a predictive biomarker of disease progression in many malignancies, including imatinib-treated chronic myeloid leukemia (CML). This evidence concerns the gene CIP2A and chronic myelogenous leukemia, BCR-ABL1 positive.